Libaccord
Supercooled Liquid Nitrogen for Treatment of Arrhythmia
StartupLibaccord is a Haifa-based startup in the Health Tech & Life Sciences sector, established in 2020. Supercooled Liquid Nitrogen for Treatment of Arrhythmia. Libaccord was founded by Gregory Golovchiner and Yakov Nedlin. The company has 1-10 employees.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQHaifa
- DistrictNorth District
- Last RoundUndisclosed
Gregory GolovchinerCo-founder Yakov NedlinCo-founder & CTO
1 article covered by sources including www.haaretz.co.il.
What does Libaccord do?
Libaccord is the developer of an innovative device for treating ventricular and atrial arrhythmias using super-cooled liquid nitrogen. Based on the deepest possible ablation (transmural), the companys solution uses the novel clinical approach of scar homogenization to reduce procedure time and includes built-in ablation depth feedback to ensure performance and safety.
Who founded Libaccord?
Libaccord was founded in 2020 by Gregory Golovchiner (Co-founder ), Yakov Nedlin (Co-founder & CTO).
What sector is Libaccord in?
Libaccord operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Libaccord located?
Libaccord is based in Haifa, Israel, North District.